Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma

A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes

(2016) Wieneke A. Buikhuisen et al.   Journal of Thoracic Oncology

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

(2016) Gérard Zalcman et al.   LANCET

Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations

(2016) Raphael Bueno et al.   NATURE GENETICS

Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions

(2014) Naveen S. Vasudev et al.   ANGIOGENESIS

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

(2014) Martin Reck et al.   LANCET ONCOLOGY

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma

(2013) G L Ceresoli et al.   BRITISH JOURNAL OF CANCER

Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy

(2013) Sophie Papa et al.   Journal of Thoracic Oncology

Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study

(2013) Wieneke A Buikhuisen et al.   LANCET ONCOLOGY

A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma

(2013) Anna K. Nowak et al.   LUNG CANCER

Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma

(2012) Hedy L. Kindler et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and Leukemia Group B 30601): A Brief Report

(2012) Arkadiusz Z. Dudek et al.   Journal of Thoracic Oncology

A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma

(2012) Anna K. Nowak et al.   Journal of Thoracic Oncology

A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma

(2012) Jonathan E. Dowell et al.   LUNG CANCER

Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509

(2011) Linda L. Garland et al.   Journal of Thoracic Oncology

Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study

(2011) Tom Treasure et al.   LANCET ONCOLOGY

The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine

(2011) Steven Chuan-Hao Kao et al.   LUNG CANCER

Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107)

(2011) Thierry Jahan et al.   LUNG CANCER

The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents

(2010) Dietmar W. Siemann   CANCER TREATMENT REVIEWS

Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma

(2010) Janna Paulsson et al.   INTERNATIONAL JOURNAL OF CANCER

Phase II Study of Asparagine-Glycine-Arginine–Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma

(2010) Vanesa Gregorc et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307

(2010) Sarita Dubey et al.   Journal of Thoracic Oncology

Clinical Significance of Serum Vascular Endothelial Growth Factor in Malignant Pleural Mesothelioma

(2010) Akihiro Yasumitsu et al.   Journal of Thoracic Oncology

Regulation of Angiogenesis by Macrophages, Dendritic Cells, and Circulating Myelomonocytic Cells

(2009) Zhao (David) Dong et al.   CURRENT PHARMACEUTICAL DESIGN

Cellular and molecular pathways linking inflammation and cancer

(2009) Chiara Porta et al.   IMMUNOBIOLOGY

Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system

(2009) Hellmut G. Augustin et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Imaging angiogenesis and the microenvironment 

(2008) DAI FUKUMURA et al.   APMIS

Tumour vascular disrupting agents: combating treatment resistance

(2008) G M Tozer et al.   BRITISH JOURNAL OF RADIOLOGY

Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents

(2008) Yuval Shaked et al.   CANCER CELL

Profiling Tumor-Associated Markers for Early Detection of Malignant Mesothelioma: An Epidemiologic Study

(2008) M. Amati et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Imatinib Mesylate Enhances Therapeutic Effects of Gemcitabine in Human Malignant Mesothelioma Xenografts

(2008) P. Bertino et al.   CLINICAL CANCER RESEARCH

Pathways Mediating Resistance to Vascular Endothelial Growth Factor-Targeted Therapy

(2008) L. M. Ellis et al.   CLINICAL CANCER RESEARCH

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY